Context Therapeutics
CNTX
24 hedge funds and large institutions have $2.55M invested in Context Therapeutics in 2022 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 7 closing their positions.
0% more funds holding
Funds holding: 24 → 24 (0)
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
0% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 6
1.55% less ownership
Funds ownership: 25.87% → 24.32% (-1.6%)
45% less capital invested
Capital invested by funds: $4.59M → $2.55M (-$2.04M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$114K |
| 2 |
S
swisspartners
Vaduz,
Liechtenstein
|
+$102K |
| 3 |
VF
Virtu Financial
New York
|
+$61.9K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$15.1K |
| 5 |
AWM
Aspire Wealth Management
Waltham,
Massachusetts
|
+$10.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$159K |
| 2 |
KCM
Knoll Capital Management
Miami,
Florida
|
-$155K |
| 3 |
V
Veritable
Wilmington,
Delaware
|
-$122K |
| 4 |
Jane Street
New York
|
-$56.3K |
| 5 |
QC
Quadrature Capital
London,
United Kingdom
|
-$51K |
CNTX Hedge Fund Activity: Q4 2022 in Review
24 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Context Therapeutics (CNTX) for Q4 2022, worth a combined $2.55M — down 45% from $4.59M a quarter earlier.
Fund positioning in CNTX was balanced in Q4 2022: 7 funds opened new positions, 7 closed out, 6 added to existing stakes and 6 trimmed.
The largest buyer was Bridgeway Capital Management, opening a new position worth an estimated $114K. The largest seller was AIGH Capital Management, cutting an estimated $159K.
- 24 institutional investors held Context Therapeutics (CNTX) as of Q4 2022, unchanged from Q3 2022.
- Funds reported $2.55M of Context Therapeutics stock for Q4 2022, down 45% quarter-over-quarter.
- 7 funds opened new Context Therapeutics positions in Q4 2022 and 7 closed out, a net change of 0 holders.
- The largest Context Therapeutics buyer in Q4 2022 was Bridgeway Capital Management, an estimated $114K added.
- The largest Context Therapeutics seller in Q4 2022 was AIGH Capital Management, an estimated $159K sold.
Based on aggregated 13F filings for Q4 2022.